Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment

Vijayakumar Javalkar, MD, MCh; Okkes Kuybu, MD; Abdallah Amireh, MD; Roger E. Kelley, MD


South Med J. 2020;113(11):585-592. 

In This Article

Cerebral Venous Thrombosis (CVT)

Despite the paucity of RCT confirmation, anticoagulant therapy in CVT is typically treated with a course of anticoagulant therapy. In a recent study of dabigatran compared with dose-adjusted warfarin in patients with CVT,[3] there was a very low risk of recurrent venous thrombotic events in both groups, specifically none observed over the 24-week observation period, with a similar risk of bleeding.